Docosahexaenoic Acid, Folic Acid and Vitamin B6: study protocols
4 study groups took Docosahexaenoic Acid together with Folic Acid and Vitamin B6. These are the doses the studies gave. They are not a recommendation.
Fewer than 5 study groups in one unit match, too few to draw the chart.
Commonly used together
4 of 4 study groups took Docosahexaenoic Acid, Folic Acid and Vitamin B6 with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Vitamin B12 | 4 |
4 study groups
| Study | |||||
|---|---|---|---|---|---|
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active group (RCT1, RCT2 and RCT3) · Men and women aged 50 years or older with mild or mild-to-moderate Alzheimer's disease; RCT3 participants were on stable approved Alzheimer's medication, while RCT1 and RCT2 participants were drug-free for Alzheimer's medication. | 1.2 g | 400 mcg | 1 mg | 24 weeks | 501 |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active product during open-label extension (OLE) · Men and women aged 50 years or older with mild Alzheimer's disease who completed RCT2. | 1.2 g | 400 mcg | 1 mg | 24 weeks | 201 |
| Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial 2020 · DHA treatment arm · Cognitively unimpaired men and women aged 55 years and older with a first-degree family history of dementia | 2.15 g | 800 mcg | 100 mg | 26 weeks | 18 |
| The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial 2017 · Test product (Souvenaid/Fortasyn Connect) · Adults aged 50 years or older with mild probable or possible Alzheimer’s disease | 1.2 g | 400 mcg | 1 mg | 4 weeks | 16 |